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BACKGROUND: Loss of CD9 expression has been correlated with a higher motility and metastatic potential of tumour cells originating
from different organs. However, the mechanism underlying this loss is not yet understood.
METHODS: We produced a truncated form of partner 1 of CD9 (CD9P-1), GS-168AT2, and developed a new monoclonal antibody
directed towards the latter. We measured the expression of CD9 and CD9P-1 in human lung tumours (hLTs), and monitored the
level of CD9 in NCI-H460, in vitro and in vivo, in the presence and absence of GS-168AT2.
RESULTS: Loss of CD9 is inversely related to the expression of CD9P-1, which correlates with the metastatic status of hLT (n¼55).
In vitro, GS-168AT2 is rapidly internalised and degraded at both the membrane and cytoplasm of NCI-H460, and this correlates with
the association of GS-168AT2 with both CD9 and CD81. Intraperitoneal injections of GS-168AT2 in NCI-H460-xenografted Nude
mice led to drastic inhibition of tumour growth, as well as to the downregulation of CD9, but not of CD81, in the tumour core.
CONCLUSION: These findings show for the first time that CD9P-1 expression positively correlates with the metastatic status of hLT,
and that the upregulation of CD9P-1 expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.
Our study also reveals that, under certain conditions, loss of CD9 could be a tumour growth-limiting phenomenon rather than a
tumour growth-promoting one.
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The tetraspanin protein family consists of 33 similar but distinct
transmembrane proteins characterised by four transmembrane
domains, two intracellular tails corresponding to the N- and
C-termini of the protein, small and large extracellular spans, and
some conserved amino-acid structures within both small and large
extracellular domains. They are, nonetheless, structurally distinct,
as they show 50–70% of sequence variability (for review see
Charrin et al (2009)). Functionally, it is well established
that tetraspanins associate with each other and with other cell
surface proteins and receptors to form functional signalling
platforms (Maecker et al, 1997; Boucheix et al, 2001; Boucheix
and Rubinstein, 2001; Hemler, 2003, 2005; Tarrant et al, 2003;
Yunta and Lazo, 2003; Lazo, 2007).
CD9, the most studied tetraspanin, is known to function in
multiple cell events, including membrane fusion (Chen et al, 1999),
differentiation (Xu et al, 1994; Choi et al, 2008), and cell motility
(Kotha et al, 2008; Takeda et al, 2008), and seems to have a key role
in metastasis (Zo ¨ller, 2009). Clinical observations suggest
that downregulation of CD9 is associated with the progression of
solid tumours. Recently, it was shown that small-cell lung cancer
cell lines have no or very few CD9 (Funakoshi et al, 2003).
Furthermore, loss of CD9 has been correlated with a higher
motility and metastatic potential of the following tumour cells:
lung (Higashiyama et al, 1995; Funakoshi et al, 2003; Wang et al,
2005), oral (Kusukawa et al, 2001), oesophageal (Uchida et al,
1999), ovarian (Houle et al, 2002), cervical (Sauer et al, 2003), and
gastric (Murayama et al, 2002). Although CD9 has been
investigated in the progression and invasion of tumours, nothing
or little has been shown about its main partner, an Ig superfamily
member called partner 1 of CD9 (CD9P-1)/FPRP/EWI-F.
Partner 1 of CD9 is a glycosylated, type 1 integral membrane
protein (Andre ´ et al, 2007), originally identified and characterised
because of its ability to associate with and inhibit [
3H]prostaglan-
din F2a binding to its receptor (Orlicky, 1996). Partner 1 of CD9 is
associated with lipid accumulation (Orlicky et al, 1998), and
gangliosides are a regulatory component of tetraspanin complexes
and in particular of CD9 (Ono et al, 2001). Partner 1 of CD9 has
been identified as a strong partner of protein CD9 (Charrin et al,
2001; Stipp et al, 2001) and as a member of the tetraspanin
web (Charrin et al, 2003). Interestingly, we have shown that
TNFa induces CD9P-1 expression in human endothelial cells
(hEC), and that a truncated form of CD9P-1, named GS-168AT2,
corresponding to the most membrane-adjacent part of the
integral protein, dose-dependently inhibited in vitro angiogenesis
(Colin et al, submitted).
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in human lung tumour (hLT) samples, and show that CD9P-1
expression at both transcriptional and translational levels corre-
lates with the metastatic status of lung tumours, in particular at the
migratory edge of the tumours. Incubation of GS-168AT2 with the
hLT cell line NCI-H460 leads to the association of GS-168AT2 with
both CD9 and CD81, and treatment of NCI-H460-xenografted
Nude mice with GS-168AT2 leads to a drastic inhibition of tumour
growth, which is associated with the in vivo downregulation
of CD9 in tumours.
MATERIALS AND METHODS
Animals, cell lines, and products
Female BALB/C (8 weeks) and BALB/C nu/nu (5 weeks) were
purchased from Charles Rivers (St Germain, France). Myeloma cell
lines Sp2/O-Ag14, PEG, and HAT were obtained from Sigma
(St-Quentin-Fallavier, France), whereas the NCI-H460 cell line was
obtained from American Type Culture Collection. Phosphate-
buffered saline, Trypsin-EDTA (Versene, Lonza, Levallois-Perret,
France), fetal calf serum (FCS), and culture medium were from
Eurobio (Courtaboeuf, France). Superscript II enzyme and RNase
inhibitor were from Invitrogen (Cergy Pontoise, France) and
the Taq polymerase enzyme was from New England Biolabs
(Wilburg, UK). CD9 polyclonal antibodies (Clone H-110), CD81
monoclonal antibody (clone 5A6, sc23962), anti-mouse-HRP or
anti-rabbit-HRP were from Santa Cruz. The 1F11 mAb was kindly
provided by Dr E Rubinstein (U602, INSERM, Villejuif, France)
Cell culture
The NCI-H460 cell line was grown in RPMI containing 10% FCS
at 371C and 5% CO2 humidified atmosphere. The absence of
mycoplasms was confirmed by using the PCR Mycoplasma
Detection kit (Takara, Lonza).
hLT biopsies and RT–PCR
Biopsy samples were collected from patients with pulmonary
tumours by curative resectional surgery and were kindly given
by the Institut Mutualiste Montsouris (Paris, France) with the
agreement of its ethical committee. Tumour staging was based on
the pTNM pathological classification. The 55 hLTs were classified
into four groups on the basis of the pTNM pathological
classification, where T (cis 1–4) represents the size or direct
extent of the primary tumour size; N represents the degree of
regional lymph node metastasis (being: N0, tumour cells absent
from regional lymph nodes; N1, closest or small number
of regional lymph node metastasis present; N2, tumour spread to
a number of and relatively distant regional lymph nodes;
N3, tumour spread to more distant or numerous regional lymph
nodes); and M represents metastasis to distant organs (beyond
regional lymph nodes). Thus, throughout our study, we considered
pT N0 as being the non-metastatic primary hLT, pT N1 as the
weakly metastatic primary hLT, pT N2 as the highly metastatic
primary hLT, and pT M as the highly metastatic secondary hLT
(tumours from distant organs that metastased into the lungs).
Tumours and their peripheral tissues recognised as healthy
tissues were immediately immersed into RNA conservative
solution and conserved at  801C. For semiquantitative RT–PCR,
total RNA was extracted using a NucleoSpin RNA II kit (Macherey
Nagel, Lonza). One microgram of total RNA was reverse-
transcribed using Superscript III reverse transcriptase according
to the manufacturer’s instructions. The generated cDNAs were
amplified with Taq polymerase according to the manufacturer’s
instructions using primers for CD9P-1 (50-AGGTCCACTG
CAGGGGGTTA-30 and 50-TTCCCCTTTGGAAGAGAGAGCA-30);
for CD9 (50-TTGCTGTCCTTGCCATTGGA-30 and 50-CACTGGGA
CTCCTGCACAGC-30); for GAPDH (used as the internal control)
(50-AGCTCACTGGCATGGCCTTC-30 and 50-GAGGTCCACCACC
CTGTTGC-30). The reaction mixtures were subjected to 30 PCR
amplification cycles (30s at 941C, 30s at 601C, 1min at 721C). The
amplified DNA samples resolved on 1.5% agarose gels, were
visualised with ethidium bromide, and quantified with Gene tools
software (Syngene, Lonza). For each biopsy including tumour core
and peripheral tissues, CD9 and CD9P-1 expression levels were
quantified relative to their respective GAPDH, and results were
expressed as the mean±s.d. of three independent experiments.
Cloning, production, and purification of the recombinant
protein GS-168AT2
The truncated form of CD9P-1, GS-168AT2, was cloned, produced,
and purified according to Colin et al (Submitted). We have also
cloned, produced, and purified another recombinant protein
corresponding to a truncated form of the cell surface tetraspanin
7/TM4SF2 (gene accession number: emb|CAB65594.1|; gene ID:
7102 TSPAN7) (amino acid no. 176–218). The purified recombi-
nant protein has a molecular mass of 16kDa and is used as a
negative control protein (NCP) in animal experiments.
Immunisation of animals and generation and selection
of hybridomas
Female BALB/C mice (8 weeks) were intraperitoneally (i.p.)
injected with 100-mg GS-168AT2 supplemented with Freund’s
complete adjuvant (1/1 (v/v)), followed by two injections at
3-week intervals, and a final boost with 100-mg GS-168AT2. After 3
days, the spleen was harvested and fused with the myeloma cell
line Sp2/O-Ag14 using 50% PEG diluted in RPMI-1640 medium,
and the fused cells were cultured in RPMI-1640 containing 15%
FCS and HAT (Eurobio) and 10% hyridoma cloning factor (PAA
Laboratories, Les Mureaux, France). Supernatants were screened
by ELISA using GS-168AT2 as antigen, His-Tag proteins (devel-
oped in our laboratory) as control, and the anti-mouse IgG-HRP
conjugate. Positive hybridomas were isolated, subjected to three
rounds of dilution limit, and one hybridoma was selected. This
was cloned, and by extension the antibody secreted was called
229T mAb.
Ascitic fluids production and mAbs purification
BALB/c mice were i.p. injected with 300ml of incomplete Freund’s
adjuvant, inoculated with 6 10
6 hybridoma cells 24h later, and
ascitic fluid was collected 8 days later. Ascitic fluids were diluted in
20mM PBS and loaded onto a G-protein affinity column (Hitrap
protein; Amersham, Pantin, France) mounted onto an HPLC
system (Actabasic; Amersham). Following extensive washing, the
IgG fractions were pulled together by elution with 0.1 M glycine
(pH 2.7). Proteins were determined by Bradford assay, purity was
controlled by SDS–PAGE, and titration was realised by ELISA as
described above.
Immunoprecipitation
The cell monolayer was washed twice with cold PBS, and lysed with
1% Triton X-100 buffer for 1h at 41C. Proteins were immunopre-
cipitated by adding 2mg of 229T mAb or 5mg of anti-CD9 or anti-
CD81 (1h at 41C); the immune complexes were harvested with
protein G-Sepharose beads (Santa Cruz), washed with lysis buffer,
resolved in SDS–PAGE, and proteins were transferred to PVDF
membrane and revealed with the indicated antibody.
For immunoprecipitation in denaturing conditions, cell layers
were washed three times with cold PBS, and lysed in cold lysis
buffer 1% SDS, 5mM EDTA, and 10mM DTT (denaturing
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precipitate GS-168AT2 and CD9P-1 proteins, H-460 cell lysates
treated in denaturing or non-denaturing conditions were supple-
mented with either GS-168AT2 (1mg) or vehicle.
Cell membrane preparations
Cytosolic and nuclear extracts were prepared by the modified
method of Dignam et al (1983). After different incubation times
with GS-168AT2, NCI-H460 cells were washed with cold PBS,
lysed in ice-cold lysis buffer (5mM HEPES, 1.5mM MgCl2,1 0 m M
KCl, 0.5mM dithiothreitol, 0.1mM PMSF, and 0.1mM aprotinin),
and centrifuged at 10
4g for 30min at 41C. The supernatant was
collected as the cytosolic fraction. Pellets were homogenised in the
above-mentioned lysis buffer containing 2% Triton X-114 (Sigma)
and centrifuged at 800g for 10min at 41C. The supernatant was
collected and is referred to here as the membrane fraction.
Immunohistochemistry on tumour sections
After de-paraffination with Histolemon reagent (CarloErba, Lonza)
and rehydration, epitopes were retrieved with MS-Unmarker
(Diapath) using a microwave oven. Endogenous peroxidases were
blocked by 0.3% H2O2 for 30min. After washing with PBS, sections
were blocked with horse serum (1:100) for 30min, and incubated in
a sodium phosphate and citric acid buffer (pH¼8.4). Ac 229
(100mgml
 1) was incubated for 30min at 371C. Bound antibodies
were detected with biotinylated horse anti-mouse Ig and avidin-HRP
(Cliniscience, Montrouge, France). Counterstaining was performed
with hemalun Mayer, followed by treatment with a bluing reagent.
Tumour xenografts in nude mice and GS-168AT2
administration
All experiments were reviewed by Genopole’s institutional animal
care and use committee, and performed in accordance with
institutional guidelines for animal care. Female BALB/c nu/nu
mice (n¼31) were used at 5–6 weeks of age. The animals were
housed in laminar air-flow cabinets under pathogen-free condi-
tions with a 14h light/10h dark schedule, and fed autoclaved
standard chow and water ad libitum. NCI-H460 cells (5 10
6 cells
in 200ml of serum-free RPMI) were subcutaneously injected into
the right flank of mice. After engraftment (10 days), tumour
volume (TV) was measured (Balsari et al, 2004) and animals were
randomised and separated into seven groups of five animals each,
to be treated by i.p. injection (200ml per injection) every other day
for 16 days (eight injections). Control mice (group 1) received
the vehicle (2 M urea in 0.9% saline). Cis-diammine platinum II
dichloride (CDDP; Sigma) was dissolved in 0.9% saline at
0.5mgml
 1 and injected at a dose of 5mgkg
 1 (group 2).
NCP was dissolved in vehicle at 1.5mgml
 1 and injected at a
dose of 15mgkg
 1 (group 3). GS-168AT2 was dissolved in vehicle
at 1.5mgml
 1 and injected at a dose of 15mgkg
 1 (group 4).
In group 5, mice received both CDDP and GS-168AT2. Tumour
volume and body weight were measured every other day over the
treatment period (16 days).
In another series of experiments, two groups of three animals
each were xenografted with NCI-H460 as above, after which,
starting from day 10 post xenograft, animals were treated daily
with either vehicle or GS-168AT2 for 5 days, and tumour blocks
were harvested at the end of treatment for analysis.
Statistics
All data were analysed with Prism 5 using the Mann–Whitney test
and the unpaired t-test. For CD9 and CD9P-1 expression, medians
were calculated and considered significantly different when the
two-tailed P-value was o0.05. All data are presented as mean
±s.d., where n is the number of independent experiments.
A P-value o0.05 was considered to be significant.
RESULTS
Production and characterisation of the new mAb
antitruncated form of CD9P-1
Following immunisation, selection, and limit dilution, isotyping
results show that the culture medium of the selected clone
(clone number 229T) contained only IgG1. This IgG1 recognised
GS-168AT2 in ELISA, and failed to recognise CD9P-1 in flow
cytometry (data not shown).
Experimentation with 229T mAb showed that, in dot-blot
assays, it did not recognise many His-Tag proteins; however, it
recognised GS-168AT2 (Figure 1A). The 229T mAb did not
immunoprecipitate CD9P-1 under native conditions, but it did
under denaturating conditions (data not shown). In western blot,
229T mAbs recognised CD9P-1 in cell lysates and in GS-168AT2
alone (Figure 1B, lanes 1 and 2, respectively). To further validate
the 229T mAb, we used 1F11 mAb (Charrin et al, 2001) to
immunoprecipitate CD9P-1 from cell lysates alone or supplemen-
ted with GS-168AT2. Resolving the immunoprecipitates in
SDS–PAGE and western blotting showed that 229T mAb
recognised the band of 135kDa immunoprecipitated with 1F11
mAb, which corresponds to CD9P-1 (Figure 1B, lanes 3 and 4), as
well as 18 and 36kDa bands corresponding to the monomer and
dimer of GS-168AT2, respectively (Figure 1B, lane 4). Of interest,
the 229T mAb also recognised other bands of molecular weight
lower than that of CD9P-1 (Figure 1B, lanes 3 and 4), which could
be proteolytic fragments of CD9P-1 generated either from the
preparation of cell lysates or from the natural turnover of CD9P-1.
Human microvascular endothelial cells (HMECs) were also
transformed with a pci-neovector coding for an antisense
transcript specific to CD9P-1. Western blotting of cell lysates
of wild HMEC and those of the HMEC cell line stably expressing
pci-neovector coding for an antisense transcript specific to CD9P-1
showed that the 229T mAb recognised the band (135kDa)
corresponding to CD9P-1 in lysates of wild HMEC (Figure 1C,
lane 1), but not in lysates of the HMEC cell line stably expressing
pci-neovector coding for an antisense transcript specific to CD9P-1
(Figure 1C, lane 2).
Finally, the NCI-H460 tumour cell line was transfected either
with siRNA specific to CD9P-1 or with nonspecific siRNA as
control. Immunoblotting of cell lysates showed that the 229T mAb
recognised the band of CD9P-1 (E135kDa) to a much less extent
(E50% decrease) in lysates issued from cells transfected with
siRNA specific to CD9P-1 compared with those issued from cells
transfected with nonspecific siRNA (Figure 1D).
CD9P-1 is overexpressed in metastasis
We studied 55 hLT biopsies (including 17 cases of secondary hLT)
for CD9 and CD9P-1 gene expression, using the CD9 index (CD9
mRNA level in tumour core relative to CD9 mRNA in surrounding
tissues) and the CD9P-1 index (CD9P-1 mRNA level in tumour core
relative to CD9P-1 mRNA in surrounding tissues). Nine of
20 cases (45%) of primary hLT (pT N0) showed CD9P-1 index
superior to 1, indicating more CD9P-1 mRNA within tumour cores
than in their surrounding tissues. In all, 54% (6 of 11) cases of
metastatic primary hLT pT N1 and 57.1% (3 of 7) cases
of pT N2 have CD9P-1 superior to 1. For secondary hLT, 76.4%
(13 of 17 cases) expressed CD9P-1 index superior to 1 (Figure 2A).
Intergroup analysis of the magnitude of CD9P-1 index and its
distribution showed that there was no significant difference
between the groups of primary hLT (pT N0) and metastatic
primary hLT pT N1 (mean CD9P-1 index±s.e.m.: 0.872±0.105
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Figure 1 Characterisation of 229T mAbs. (A) GS-168AT2 (4) and other His-Tag recombinant proteins (2, 3) or vehicle (1) were immobilised on
nitrocellulose membrane, immunoblotted with 229T mAb, and revealed with anti-mouse-HRP antibody. (B) Cell lysates of NCI-H460 tumour
supplemented with GS-168AT2 (lane 1) or GS-168AT2 alone (lane 2), as well as immunoprecipitates obtained with 1F11 mAb either from NCI-H460
tumour lysates alone (lane 3) or from those supplemented with GS-168AT2 (lane 4) were resolved in SDS–PAGE and immunoblotted with 229T mAb.
Representative image of the western blot of three independent experiments is presented. (C) Cell lysates of either wild human microvascular endothelial
cells (lane 1) or human microvascular endothelial cells constitutively expressing antisense transcript of CD9P-1 (lane 2) were resolved in SDS–PAGE and
immunoblotted with 229T mAb. Representative image of the western blot of four independent experiments is presented. (D) NCI-H-460 cells were
transfected either with nonspecific siRNA (siRNAc) as control or with siRNA specific to CD9P-1 (siRNA CD9P-1), or incubated with siRNA-free
transfection cocktail (control). Cell lysates were prepared and resolved in SDS–PAGE and immunoblotted either with 229T mAb (upper panel) or with
anti-actin antibody (lower panel) as internal control. Partner 1 of CD9 expression was then appreciated (middle panel) relative to the internal control (actin).
Results representative of two independent experiments are presented.
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Figure 2 Partner 1 of CD9 expression correlates with the metastatic status of human lung tumours. (A) Fifty-five biopsy samples of hLTs, as well as of
their surrounding tissues, were classified according to the TNM staging system, and the expression of CD9P-1 was quantified at both the tumour core and
the surrounding tissues by RT–PCR relative to GAPDH. Results are presented as the percentage of cases (for each class of tumours) that have a ratio 41o f
CD9P-1 at the tumour core relative to CD9P-1 at the surrounding tissue. (B) Distribution of the CD9P-1 index (ratio of CD9P-1 at the tumour core
relative to CD9P-1 at surrounding tissues) of the different classified groups. (C) The expression of CD9 was quantified at both the tumour core and
surrounding tissues by RT–PCR relative to GAPDH using hLT as in (A). Results are presented as the percentage of cases (for each class of tumours)
that have a ratio 41 of CD9 at the tumour core relative to CD9 at surrounding tissues. (D) Distribution of the CD9 index (ratio of CD9 at the tumour core
relative to CD9 at surrounding tissues) of the different classified groups.
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sand 1.295±0.224, respectively; P¼0.0619; 95% CI¼ 0.868
to 0.0224; Figure 2B). In contrast, the group of metastatic primary
hLT (pT N2) showed a highly significant difference (mean
CD9P-1 index±s.e.m.: 2.179±0.436; P¼0.0003; 95% CI¼ 1.938
to  0.6739) compared with the group of primary hLT (pT N0)
(Figure 2B).
The secondary lung metastasis group hLT (M) also showed a
significant difference (mean CD9P-1 index±s.e.m.: 4.098±1.041;
P¼0.002; 95% CI¼ 5.184 to  1.266) compared with the group of
primary hLT (pT N0) (Figure 2B).
For CD9 gene expression, 27.3% of non-metastatic primary lung
tumours (pT N0) expressed CD9 mRNA more at tumour cores
than in their surrounding tissues (Figure 2C). CD9 gene expression
within metastatic primary lung tumours (pT N1and pT N2)
and secondary lung metastasis (M) showed a direct correlation
between the downregulation of CD9 expression and the metastatic
status of hLT; 70, 30, and 22.2% of pT N1, pT N2, and M,
respectively, expressed CD9 more in tumour cores than in their
surrounding tissues (Figure 2C).
The magnitude and distribution analysis of CD9 showed
that there were no significant differences (P40.05) between the
group of primary hLT (pT N0) (mean CD9 index±s.e.m.:
0.807±0.269) and any of the other groups, namely, pT N1
(mean CD9 index±s.e.m.: 1.31±0.138), pT N2 (mean CD9
index±s.e.m.: 0.79±0.14), and M (mean CD9 index±s.e.m.:
0.663±0.118). In contrast, the group of metastatic primary hLT
(pT N2) showed a significant difference (P¼0.035; 95%
CI¼0.0428–0.999) compared with the group of metastatic
primary hLT (pT N1) (Figure 2D). The secondary metastasis
group hLT (M) also showed a highly significant difference
(P¼0.002; 95% CI¼0.262–1.041) compared with the group of
primary hLT (pT N0) (Figure 2D).
Partner 1 of CD9 expression at the protein level was also
investigated. Immunostaining of human cancer biopsy samples
with 229T mAb showed that there was important staining of
individual tumour cells (migratory cells) within tissue sections
(Figures 3A–C), suggesting that an induced expression of CD9P-1
is associated with the migratory character of tumour cells. The
possibility that the upregulation CD9P-1 protein expression
associates with the migratory character of tumour cells was also
more visible in Figure 3D, in which tumour cells at the migratory
edge were clearly positively stained.
Tumour cell interaction with GS-168AT2 leads to its
degradation
To provide insight into the fate of GS-168AT2, cells incubated with
it were fractionated into cytoplasm and membrane fractions.
Western blot with 229T mAb showed weak quantity with a peak of
intact GS-168AT2 at 1h associated with a degraded form (about
16kDa) of GS-168AT2 throughout the kinetics at the membrane
fractions, indicating that GS-168AT2 could be cleaved at mem-
branes as early as 30min (Figure 4). Results of the cytoplasm
fractions showed that there is an important quantity of intact
GS-168AT2 throughout the kinetics associated with increasing
quantities of a degraded form (about 15.5kDa) of GS-168AT2 up
to 2h, suggesting that GS-168AT2 interacts with the NCI-H460
surface, leading to its degradation (Figure 4).
GS-168AT2 interacts with CD9 and CD81
The possible interaction of GS-168AT2 with CD9 and CD81
was investigated. NCI-H460 cells were incubated for 2h with
GS-168AT2, lysed under non-denaturing conditions, and immuno-
precipitation was realised with either anti-CD9, anti-CD81, or 229T
mAb. As described above, 229T mAb did not immunoprecipitate
CD9P-1 under non-denaturing conditions, but led to the
immunoprecipitation of GS-168AT2 and fragments, confirming
the results observed by western blot. Immunoprecipitation with
229T mAb did not co-precipitate CD9, probably because of the
engagement of the epitope of GS-168AT2 with CD9. On the other
hand, immunoprecipitation of either CD9 or CD81 led not only to
the co-precipitation of CD9P-1 but also to the co-precipitation of
GS-168AT2, suggesting the direct interaction between GS-168aT2
with CD9 and CD81 (Figure 5A). Traces of cleaved fragments were
also observed.
Figure 3 Partner 1 of CD9 protein expression is associated with the edge migratory front of tumours. CD9P-1 immunolabelling with 229T mAb in
pulmonary metastasis adenocarcinoma from the prostate (A–C). The strong labelling with the 229T mAb of the edge migratory front of tumours
is shown in (D).
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proteins, we have also immunoprecipitated integrin-b1 and the
receptor of vascular endothelial cell receptor (Flk). Immunoblot-
ting with 229T mAb revealed that there was no detectable
co-precipitation of GS-168AT2 with these cell surface proteins
(Figure 5A), thereby confirming that GS-168AT2 specifically
co-precipitated with CD9 and CD81.
The immunoprecipitates obtained with 229T mAb or anti-CD9
were also resolved in SDS–PAGE and blotted with anti-CD9.
Results showed that CD9 was effectively immunoprecipitated
(Figure 5B).
GS-168AT2 inhibits the in vivo hLT growth
All nude mice bearing NCI-H460 tumours survived during the
therapy. Before therapy, there were no significant differences
among nude mice with respect to weight and TV. The results of
mean tumour volume (MTV) and mean relative tumour volume
(MRTV) are shown in Figures 6A–C. The MTV at day 28 in mice
of group 2 treated with NCP is similar to that of mice treated with
vehicle (group 1) and there were no significant differences between
the two groups (P40.05) (Figure 6A). The MTV at day 28 in
mice of group 3 treated with CDDP (1203.48±240.69mm
3)i s
significantly (P¼0.001) less than that of mice of vehicle group 1
(2220.34±555.08mm
3) (Figure 7B). The MTV at day 28 was
decreased (P¼0.001) in mice of group 4 treated with GS-168AT2
alone (958.38±287.51mm
3). The first statistical significance
between group 1 and the other groups was observed at day 4
post treatment for groups 4 and 5 (Figure 6B). An important
reduction in MTV (364.22±105.62mm
3) was observed in animals
from group 5 compared with those from group 1 (P¼0.0001).
These results were confirmed by analysis of MRTV at day 28
(Figure 6C). GS-168AT2, when used as a monotherapy, reduced
tumour growth by at least 50% compared with group 1. When
combined with CDDP, however, this reduction reached 83%.
Tumours were extracted from animals at the end of the
treatments and lysed. Immunoblotting with the anti-CD81 anti-
body of these lysates showed that tumours treated with vehicle and
those treated with GS-168AT2 contained equivalent amounts of
CD81 at the end of the treatments (Figure 7A).
Immunoblotting with the anti-CD9 antibody of tumour lysates
at the end of the treatments showed that tumours of vehicle-treated
animals contained an important quantity of CD9. However, in
tumours of GS-168AT2-treated animals, only trace amounts of
CD9 were detected (Figure 7B). To give further insight into the
chronology of the loss of CD9 with treatment with GS-168AT2, two
groups of animals (three animals per group) xenografted with
NCI-H460 tumours as above were treated for 5 days with either
vehicle or GS-168AT2, under the same conditions as above.
Analysis of CD9 showed that tumours from animals treated with
GS-168AT2 for five successive days have less CD9 than those from
animals treated with GS-168AT2 for 5 days (Figure 7B).
DISCUSSION
In this study, we have shown that CD9P-1 was upregulated in
human cancer metastasis, suggesting that this could be one of the
mechanisms underlying the loss of CD9 expression in solid
tumours. Our study also shows that this loss of CD9, when
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Figure 4 GS-168AT2 interaction with tumour cell led to its internalisa-
tion and degradation. The NCI-H460 layer was incubated with GS-168AT2
for the indicated time, washed, lysed, and fractionated into cytosol and
membrane fractions. The two fractions were resolved in SDS–PAGE,
followed by immunoblotting with 229T mAb. The two fractions were
also resolved in SDS–PAGE, followed by immunoblotting with mAb
anti-protein kinase B (Akt) (a cytoplasmic protein); results showed that Akt
was only detectable in the fraction of cytosol and not in the membrane
fraction, suggesting that there were no intercontaminations between the
two fractions. Representative image of two independent experiments is
presented.
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Figure 5 The degradation of GS-168AT2 is associated with its inter-
action with CD9 and CD81. (A) NCI-H460 cells were incubated for 2h
with (lanes labelled with þ) or without (lanes labelled with  )
GS-168AT2, followed by lysing with native lysis buffer. Proteins were
immunoprecipitated with 229T mAb (lanes labelled with IP 229T mAb),
anti-CD9 antibody (lanes labelled with IP CD9), anti-CD81 antibody (lanes
labelled with IP CD81), anti-b1-integrin antibody (lanes labelled with IP
integrin), or anti-vascular endothelial factor receptor (IP Flk 1) (lanes
labelled with IP Flk1). The obtained immunoprecipitates or total cell lysates
of cells incubated with GS-168AT2 (lane labelled with total cell lysate)
(as control) were resolved in SDS–PAGE under reducing conditions and
western blotted with 229T mAb. GS-168AT2 was undetectable with the
immunoprecipitates obtained with the anti-b1-integrin (IP b1-integrin)
antibody and with the antivascular endothelial cell growth factor receptor
(IP Flk 1), but was detectable with the immunoprecipitates obtained with
229T mAb (IP 229T mAb). Representative image of the western blot of
three independent experiments is presented. (B) The immunoprecipitates
obtained with either 229T mAb (lanes labelled with IP 229T mAb) or anti-
CD9 antibody (lanes labelled with IP CD9), in the presence or absence of
GS-168AT2 as in panel A of this figure, were also resolved in SDS–PAGE
and immunoblotted with anti-CD9 antibody. CD9 was well immunopre-
cipitated with anti-CD9 antibody under our experimental conditions,
as described in panel A.
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sassociated with the increase in CD9P-1 expression, could be a
tumour growth-limiting phenomenon. These findings are sup-
ported by several direct facts, including the following: (i) CD9P-1
expression correlated with the metastatic status of hLT and was
inversely proportional to CD9 expression; (ii) the truncated form
of CD9P-1, GS-168AT2, was rapidly internalised by tumour cells
correlating with its interaction with both CD9 and CD81; and
most importantly, (iii) treatments of hLT-xenografted Nude mice
with GS-168AT2 led to a drastic inhibition of hLT growth that was
associated with an important in vivo downregulation of CD9 in the
tumour core, but not in CD81.
Loss of CD9 is correlated with cancer metastasis in many solid
tumours (Higashiyama et al, 1995; Funakoshi et al, 2003; Wang
et al, 2005). Although CD9P-1 is present in a large panel of cancer
cell lines (Charrin et al, 2001; Vidal-Laliena et al, 2005), the role
of CD9P-1 in oncogenesis and metastasis remains unknown. Our
results show that CD9P-1 expression strongly correlates with the
metastatic status of hLT, as 45% of primary non-metastatic hLTs
express CD9P-1 more than their surrounding tissues, whereas 55%
of metastatic primary hLTs and 83% of secondary hLT metastases
express CD9P-1 more than their surrounding tissues. It was shown
recently that the transfection of HEK-293 cells with CD9P-1 coding
vector increased cell migration (Chambrion and Le Naour, 2010).
Our results extend these in vitro results, and showed that the
expression of CD9P-1 localises at the migratory edge of human
tumours.
Interestingly, CD9 expression was inversely proportional
to both CD9P-1 expression and the metastatic status of hLT. It is
worth mentioning, however, that although the association of the
loss of CD9 with the metastatic status of tumours is highly
significant and in agreement with the literature (Higashiyama et al,
1995; Adachi et al, 1998), our appreciation of CD9 expression
within the tumour core was certainly overestimated. Indeed, it is
widely established that tumour angiogenesis correlates with the
metastatic status of tumours, indicating that higher the levels of
hEC (neovessels) that are present within the tumour core, more
important the metastatic potential of the tumour. Recently, it was
shown that CD9 is highly expressed in hEC (Klein-Soyer et al,
2000), suggesting that an important source of CD9 that was
detected within the tumour core could originate from the invading
neovessels.
We previously reported that GS-168AT2 has potent antiangio-
genic activity correlating with both, its degradation by hEC and CD9
downregulation (Colin et al, Submitted). In this study, we show that
CD9 downregulation in vivo is associated with the degradation of
GS-168AT2. Our data show that most of the degraded form was
present in the cytosolic fraction, suggesting that GS-168AT2 was
internalised by NCI-H460, but we cannot exclude the contamination
of cytosolic fractions by membrane-bound GS-168AT2. The
degradation of GS-168AT2 by NCI-H460 cells is associated with
CD9 downregulation in vivo, suggesting that either native
GS-168AT2 or the GS-168AT2-derived fragments directly or
indirectly interact with CD9, leading to the internalisation of the
complex. These results are consistent with earlier results showing
that CD9P-1 is a partner of CD9 (Charrin et al,2 0 0 1 ) .
Treatment of NCI-H460-xenografted mice with GS-168AT2
(15mgkg
 1) alone for 16 days reduced tumour growth by about
50%. This effect was similar to that of treatment with CDDP alone
(5mgkg
 1), and the combined treatment of GS-168AT2 and CDDP
led to over 83% inhibition of tumour growth. This illustrates
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Figure 6 GS-168AT2 inhibits in vivo tumour growth. (A) MTV curve of mice bearing NCI-H460 tumours and treated with vehicle or nonspecific protein
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Figure 7 GS-168AT2 inhibits the in vivo tumour growth associated with
drastic in vivo downregulation of CD9 in the tumour core, but not in CD81.
(A) Tumour masses were extracted from animal cores at the end of
treatment, homogenised, resolved in SDS–PAGE, and immunoblotted
with anti-CD81 antibody. Commercial control cell lysates for CD9 (Santa
Cruz) were used as control. Lane labelled with vehicle: tumours from
animals treated with vehicle; lane labelled with GS-168AT2: tumours from
animals treated with GS-168AT2. (B) Tumour masses were extracted
from animals at the end of treatments (either after five successive days of
treatment, lanes labelled under 5 days of treatment, or after complete
treatment, as described in Figure 6 and under Materials and Methods
section), homogenised, resolved in SDS–PAGE, and immunoblotted
with either anti-CD9 antibody (upper panel) or anti-GAPDH antibody
(lower panel) as control. CD9 expression was then appreciated (middle
panel) relative to the internal control (GAPDH). Results representative of
two independent experiments are presented.
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sthe greater efficacy of bitherapies (chemotherapy associated with
antiangiogenic therapy) at reducing hLT proliferation. The
antiangiogenic activity of GS-168AT2 most probably accounts
for most of the antitumour growth effect (Colin et al, Submitted).
The efficacy of GS-168AT2 could be the sum of its direct effect on
tumour cells and its antiangiogenic activity.
In conclusion, pharmacological modulation of the tetraspanin
web affects multiple mechanisms, including tumour growth,
and angiogenesis could constitute an efficient target for cancer
therapies (Hemler, 2008).
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